Alliancebernstein L.P. Affimed N.V. Transaction History

Alliancebernstein L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $36,960 - $82,320	33,600 Added 25.57%	165,000 $204,000
Q3 2022 Nov 15, 2022	SELL	$1.96 - $3.32 $14,112 - $23,904	-7,200 Reduced 5.19%	131,400 $271,000
Q2 2022 Aug 15, 2022	SELL	$2.27 - $4.86 $541,849 - $1.16 Million	-238,700 Reduced 63.27%	138,600 $384,000
Q1 2022 May 13, 2022	BUY	$3.69 - $5.65 $923,976 - $1.41 Million	250,400 Added 197.32%	377,300 $1.65 Million
Q1 2021 May 06, 2021	BUY	$5.12 - $8.48 $288,256 - $477,424	56,300 Added 79.75%	126,900 $1 Million
Q4 2020 Feb 08, 2021	SELL	$3.16 - $7.03 $56,248 - $125,134	-17,800 Reduced 20.14%	70,600 $411,000
Q2 2020 Aug 13, 2020	BUY	$1.58 - $4.63 $90,692 - $265,762	57,400 Added 185.16%	88,400 $408,000
Q1 2020 May 14, 2020	BUY	$1.44 - $3.02 $15,264 - $32,012	10,600 Added 51.96%	31,000 $49,000
Q2 2019 Aug 14, 2019	BUY	$2.6 - $4.21 $53,040 - $85,884	20,400 New	20,400 $59,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $151M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.